BioStock-article: Aptahem comments on the paused phase I study

Aptahem develops the drug candidate Apta-1 as an acute treatment of sepsis. Recently, the company announced that the ongoing phase Ia study had been temporarily paused after observing interesting data. To learn more about the significance of this data, BioStock contacted Aptahem’s CEO Mikael Lindstam.

Read the full interview with Mikael Lindstam at biostock.se:

https://www.biostock.se/en/2023/07/aptahem-comments-on-the-paused-phase-i-study/

For further information:

Aptahem AB
Mikael Lindstam, CEO
Tel: +46 (0)766-33 36 99
E-mail: ml@aptahem.com

About Aptahem

Aptahem AB (APTA) is a clinical stage biotechnology company that develops aptamer-based pharmaceuticals for the treatment of acute, life-threatening conditions in which a combination of coagulation, inflammation and tissue damage are involved. The company’s lead candidate, Apta-1, is currently in early clinical phase. Apta-1 has in preclinical studies, by its anti-thrombotic, immunomodulating and tissue repairing characteristics, shown very positive and promising results as treatment for sepsis and critical conditions associated with sepsis. For more information, please visit www.aptahem.com.

Tags: